BioCentury | Dec 10, 2012
Clinical News

Synergy Everolimus-Eluting Platinum Chromium Coronary Stent System: Phase III started

...Boston Scientific began the single-blind, international Phase III EVOLVE II trial to compare its Synergy Everolimus-Eluting Platinum Chromium Coronary Stent System vs...
...received CE Mark approval for Synergy in October. Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Product: Synergy Everolimus-Eluting Platinum Chromium Coronary Stent System...
BioCentury | Nov 5, 2012
Clinical News

Synergy Everolimus-Eluting Platinum Chromium Coronary Stent System regulatory update

...Boston Scientific said it received CE Mark approval for its Synergy Everolimus-Eluting Platinum Chromium Coronary Stent System for coronary artery lesions. The...
...this year to support U.S. and Japanese approval. Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Product: Synergy Everolimus-Eluting Platinum Chromium Coronary Stent System...
BioCentury | Jan 31, 2011
Clinical News

Synergy stent: Completed pivotal trial enrollment

...Scientific completed enrollment of 291 patients in the single-blind, international pivotal EVOLVE trial comparing the Synergy stent...
...to support CE Mark approval of the Synergy stent. Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Product: Synergy stent...
BioCentury | Aug 9, 2010
Clinical News

Synergy stent update

...Boston Scientific began the single-blind, international pivotal EVOLVE trial to evaluate Synergy stent vs. Promus Element everolimus-eluting...
...used to support CE Mark approval of Synergy stent. Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Product: Synergy stent...
Items per page:
1 - 4 of 4